Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Brilliant Bio Pharma Ltd

    Brilliant Bio Pharma Ltd is a member company of 226 million US$ TGV conglomerate engaged in manufacture of Veterinary Biologicals and Medicines. The group has diverse activitie

  • No Image
    Brinton Pharmaceuticals Ltd

    Brinton Pharmaceuticals Ltd is present in eight countries, including Sri Lanka, Nepal and Bangladesh. It has registered offices in the US, UK and Ghana. The company intends to e

  • No Image
    Brooks Laboratories Ltd

    Brooks Laboratories Ltd. was established in 2002 and maintains its strong presence in the Pharmaceutical industry as a Contract Manufacturing Company since its inception. Brooks

  • No Image
    Cadila Healthcare Ltd

    Zydus Cadila is a fully integrated, global healthcare provider, with strengths all along the pharmaceutical value chain. With a core competence in the field of healthcare, Zydus